Dyadic International, Inc. (DYAI: OTCQX U.S. Premier) |

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Dyadic International, Inc. (DYAI: OTCQX U.S. Premier) | Dyadic International To Present At The 2014 Global Biotechnology Conference Dyadic International To Present At The 2014 Global Biotechnology Conference

Dyadic International To Present At The 2014 Global Biotechnology Conference

PR Newswire

JUPITER, Fla. , June 9, 2014 /PRNewswire/ --  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced that Dyadic's Chief Operating Officer Danai Brooks will present at the 2014 Global Biotechnology Conference on Wednesday, June 18, 2014 at 4:10 p.m. ET at the John B. Hynes Memorial Convention Center in Boston, Massachusetts . For registration information, please visit the conference website at http://www.globalbiotechcongress.com .

Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO

Mr. Brooks will conduct one-on-one meetings throughout the conference dates of June 16 – 19, 2014. Attendees can contact Dyadic investor relations to arrange a meeting.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com . Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote   .

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic's research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Annual Report filed with the OTC Markets Group on March 31, 2014 .

SOURCE Dyadic International, Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 8

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 4

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 7

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 6

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 3

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 3

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 6

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 3

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Shareholder Investigations in Various Companies

Updated Category News Views 261

Overview of Current Shareholder Investigations Brodsky & Smith, a well-known litigation law firm, is actively reminding shareholders about various ongoing investigations involving Sealed Air Corporation, Movano Inc., Gulf Island Inc., and Denny's Corporation. If you are a shareholder interested in obtaining more information regarding these investigations, you can reach...

Continue Reading
Nykredit Announces Voluntary Tender Offer for Spar Nord Bank

Updated Category News Views 147

Nykredit Announces a Voluntary Public Tender Offer for Spar Nord Bank Nykredit Realkredit A/S, a prominent player in the Danish financial landscape, has publicly unveiled its plans for a voluntary tender offer directed at Spar Nord Bank A/S. This anticipated offer, which signals Nykredit's strategic expansion ambitions, seeks to acquire all available shares in Spar Nord...

Continue Reading
Big 5 Sporting Goods Embarks on New Growth Journey After Merger

Updated Category News Views 292

Big 5 Sporting Goods Corporation Announces Merger Completion Big 5 Sporting Goods Corporation (Nasdaq: BGFV), a well-established name in the sporting goods industry, has successfully completed its merger with a partnership composed of Worldwide Golf and Capitol Hill Group. This new chapter for Big 5 is expected to propel the company towards greater heights. Merger Details...

Continue Reading
UCB's BIMZELX® Data: A Game Changer for Arthritis Care

Updated Category News Views 132

UCB's Innovative Efforts in Arthritis Treatment UCB is making significant strides in the field of rheumatology, particularly with the release of new data regarding BIMZELX® (bimekizumab-bkzx) presented at the ACR Convergence 2024. This marks the first time the company has shared data specifically relating to psoriatic arthritis (PsA), non-radiographic axial...

Continue Reading
Mega Matrix Launches Captivating Urban Romance on FlexTV

Updated Category News Views 614

Engaging Romance Premieres on FlexTV Mega Matrix Inc. (NYSE American: MPU) has unveiled a captivating romantic miniseries titled A flash Marriage With The Billionaire Tycoon, streaming on its renowned short series platform, FlexTV. This adventurous drama dives into themes of love, responsibility, and the quest for personal redemption, showcasing the complicated lives of...

Continue Reading